AMETEK, Inc. (AME) Stock Forecast
Data as of May 2, 2026Industrials · Current price $230.75 (-2.02%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 26, 2026 | Daniel DiCicco | BMO Capital | $253.00 | +9.6% |
| Feb 4, 2026 | Julian Mitchell | Barclays | $220.00 | -4.7% |
| Jan 12, 2026 | Christopher Snyder | Morgan Stanley | $215.00 | -6.8% |
| Jan 7, 2026 | Julian Mitchell | Barclays | $210.00 | -9.0% |
| Jan 5, 2026 | Rob Wertheimer | Melius Research | $235.00 | +1.8% |
| Nov 3, 2025 | Richard Eastman | Robert W. Baird | $204.00 | -11.6% |
| Oct 31, 2025 | Deane Dray | RBC Capital | $229.00 | -0.8% |
| Oct 8, 2025 | Jamie Cook | Truist Financial | $229.00 | -0.8% |
| May 16, 2025 | Brett Linzey | Mizuho Securities | $212.00 | -8.1% |
| Oct 9, 2024 | Jamie Cook | Truist Financial | $219.00 | -5.1% |
| Sep 10, 2024 | Christopher Glynn | Oppenheimer | $190.00 | -17.7% |
| Aug 2, 2024 | Scott Graham | Seaport Global | $200.00 | -13.3% |
| Jul 2, 2024 | Jamie Cook | Truist Financial | $204.00 | -11.6% |
| May 22, 2024 | Christopher Glynn | Oppenheimer | $200.00 | -13.3% |
| May 6, 2024 | Scott Graham | Seaport Global | $208.00 | -9.9% |
| May 6, 2024 | Richard Eastman | Robert W. Baird | $171.00 | -25.9% |
| Apr 4, 2024 | Deane Dray | RBC Capital | $216.00 | -6.4% |
| Mar 13, 2024 | Jamie Cook | Truist Financial | $210.00 | -9.0% |
| Aug 15, 2022 | Brett Linzey | Mizuho Securities | $140.00 | -39.3% |
| Jun 3, 2022 | Joshua Pokrzywinski | Morgan Stanley | $135.00 | -41.5% |
Top Analysts Covering AME
AME vs Sector & Market
| Metric | AME | Industrials Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.40 | 2.41 | 2.41 |
| Analyst Count | 15 | 8 | 18 |
| Target Upside | +6.6% | +85.0% | +14.9% |
| P/E Ratio | 34.86 | 28.14 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7.87B | $7.97B | $8.16B | 9 |
| 2027-03-31 | $1.98B | $2.02B | $2.04B | 4 |
| 2027-06-30 | $2.02B | $2.06B | $2.08B | 3 |
| 2027-09-30 | $2.07B | $2.11B | $2.13B | 3 |
| 2027-12-31 | $2.17B | $2.21B | $2.23B | 3 |
| 2028-03-31 | $2.10B | $2.14B | $2.16B | 2 |
| 2028-06-30 | $2.16B | $2.20B | $2.22B | 5 |
| 2028-09-30 | $2.18B | $2.23B | $2.25B | 4 |
| 2028-12-31 | $2.29B | $2.34B | $2.36B | 4 |
| 2029-12-31 | $9.19B | $9.35B | $9.65B | 5 |
| 2030-12-31 | $9.43B | $9.60B | $9.91B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7.98 | $8.06 | $8.21 | 9 |
| 2027-03-31 | $2.01 | $2.06 | $2.09 | 3 |
| 2027-06-30 | $2.07 | $2.12 | $2.15 | 5 |
| 2027-09-30 | $2.13 | $2.18 | $2.21 | 3 |
| 2027-12-31 | $2.24 | $2.30 | $2.33 | 6 |
| 2028-03-31 | $2.17 | $2.22 | $2.25 | 4 |
| 2028-06-30 | $2.22 | $2.27 | $2.30 | 6 |
| 2028-09-30 | $2.26 | $2.32 | $2.35 | 4 |
| 2028-12-31 | $2.37 | $2.43 | $2.46 | 7 |
| 2029-12-31 | $9.67 | $9.90 | $10.31 | 1 |
| 2030-12-31 | $9.58 | $9.81 | $10.22 | 1 |
Frequently Asked Questions
What is the analyst consensus for AME?
The consensus among 15 analysts covering AMETEK, Inc. (AME) is Buy with an average price target of $241.64.
What is the highest price target for AME?
The highest price target for AME is $253.00, set by Daniel DiCicco at BMO Capital on 2026-03-26.
What is the lowest price target for AME?
The lowest price target for AME is $135.00, set by Joshua Pokrzywinski at Morgan Stanley on 2022-06-03.
How many analysts cover AME?
15 analysts have issued ratings for AMETEK, Inc. in the past 12 months.
Is AME a buy or sell right now?
Based on 15 analyst ratings, AME has a consensus rating of Buy (2.40/5) with a +6.6% upside to the consensus target of $241.64.
What are the earnings estimates for AME?
Analysts estimate AME will report EPS of $8.06 for the period ending 2026-12-31, with revenue estimated at $7.97B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.